TCRTPDAC

Jianxin Wang1, Tengyi Zhang2, Pan Li1

  • 1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Cancer letters
|August 28, 2023
PubMed
概括

研究人员确定了一个特定的T细胞点,LAMC2203-211,用于胰腺管道腺癌 (PDAC) 免疫治疗. 这种针对LAMC2的T细胞疗法在体外和体内表现出强大的抗PDAC作用,为许多患者提供了有前途的策略.